Activated Proliferation of B-Cell Lymphomas/Leukemias with the SHP1 Gene Silencing by Aberrant CpG Methylation

Maho Koyama, Takashi Oka, Mamoru Oouchida, Yoko Nakatani, Ritsuo Nishiuchi, Tadashi Yoshino, Kazuhiko Hayashi, Tadaatsu Akagi, Yoshiki Seino

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Previously we showed reduced protein and mRNA expression of the SHP1 gene in lymphoma/leukemia cell lines and patient specimens by Northern blot, RT-PCR, Western blot, and immunohistochemical analyses. In this study, aberrant methylation in the SHP1 gene promoter was detected in many B-cell leukemia/lymphoma cell lines as well as in patient specimens, including diffuse large B-cell lymphoma (methylation frequency 93%), MALT lymphoma (82%), mantle cell lymphoma (75%), plasmacytoma (100%) and follicular lymphoma (96%) by methylation-specific PCR, bisulfite sequencing, and restriction enzyme-mediated PCR analyses. The methylation frequency was significantly higher in high-grade MALT lymphoma cases (100%) than in low-grade MALT lymphoma cases (70%), which correlated well with the frequency of no expression of SHP1 protein in high-grade (80%) and low-grade MALT lymphoma (54%). It suggests that the SHP1 gene silencing with aberrant CpG methylation relates to the lymphoma progression. SHP1 protein expression was recovered in B-cell lines after the treatment of the demethylating reagent: 5-aza-2′-deoxycytidine. Transfection of the intact SHP1 gene to the hematopoietic cultured cells, which show no expression of the SHP1 gene, induced growth inhibition, indicating that gene silencing of the SHP1 gene by aberrant methylation plays an important role to get the growth advantage of the malignant lymphoma/leukemia cells. The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. These data support the possibility that the SHP1 gene is one of the tumor suppressor genes.

Original languageEnglish
Pages (from-to)1849-1858
Number of pages10
JournalLaboratory Investigation
Volume83
Issue number12
DOIs
Publication statusPublished - Dec 2003

Fingerprint

B-Cell Leukemia
Gene Silencing
B-Cell Lymphoma
Methylation
Marginal Zone B-Cell Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
Leukemia
Genes
decitabine
Cell Line
Polymerase Chain Reaction
Gene Expression
Mantle-Cell Lymphoma
Follicular Lymphoma
Proteins
Plasmacytoma
Lymphoma, Large B-Cell, Diffuse
Growth
Tumor Suppressor Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Activated Proliferation of B-Cell Lymphomas/Leukemias with the SHP1 Gene Silencing by Aberrant CpG Methylation. / Koyama, Maho; Oka, Takashi; Oouchida, Mamoru; Nakatani, Yoko; Nishiuchi, Ritsuo; Yoshino, Tadashi; Hayashi, Kazuhiko; Akagi, Tadaatsu; Seino, Yoshiki.

In: Laboratory Investigation, Vol. 83, No. 12, 12.2003, p. 1849-1858.

Research output: Contribution to journalArticle

Koyama, Maho ; Oka, Takashi ; Oouchida, Mamoru ; Nakatani, Yoko ; Nishiuchi, Ritsuo ; Yoshino, Tadashi ; Hayashi, Kazuhiko ; Akagi, Tadaatsu ; Seino, Yoshiki. / Activated Proliferation of B-Cell Lymphomas/Leukemias with the SHP1 Gene Silencing by Aberrant CpG Methylation. In: Laboratory Investigation. 2003 ; Vol. 83, No. 12. pp. 1849-1858.
@article{1d3546f96a9e45a79cb7e3e6b111f478,
title = "Activated Proliferation of B-Cell Lymphomas/Leukemias with the SHP1 Gene Silencing by Aberrant CpG Methylation",
abstract = "Previously we showed reduced protein and mRNA expression of the SHP1 gene in lymphoma/leukemia cell lines and patient specimens by Northern blot, RT-PCR, Western blot, and immunohistochemical analyses. In this study, aberrant methylation in the SHP1 gene promoter was detected in many B-cell leukemia/lymphoma cell lines as well as in patient specimens, including diffuse large B-cell lymphoma (methylation frequency 93{\%}), MALT lymphoma (82{\%}), mantle cell lymphoma (75{\%}), plasmacytoma (100{\%}) and follicular lymphoma (96{\%}) by methylation-specific PCR, bisulfite sequencing, and restriction enzyme-mediated PCR analyses. The methylation frequency was significantly higher in high-grade MALT lymphoma cases (100{\%}) than in low-grade MALT lymphoma cases (70{\%}), which correlated well with the frequency of no expression of SHP1 protein in high-grade (80{\%}) and low-grade MALT lymphoma (54{\%}). It suggests that the SHP1 gene silencing with aberrant CpG methylation relates to the lymphoma progression. SHP1 protein expression was recovered in B-cell lines after the treatment of the demethylating reagent: 5-aza-2′-deoxycytidine. Transfection of the intact SHP1 gene to the hematopoietic cultured cells, which show no expression of the SHP1 gene, induced growth inhibition, indicating that gene silencing of the SHP1 gene by aberrant methylation plays an important role to get the growth advantage of the malignant lymphoma/leukemia cells. The extraordinarily high frequency (75 to 100{\%}) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. These data support the possibility that the SHP1 gene is one of the tumor suppressor genes.",
author = "Maho Koyama and Takashi Oka and Mamoru Oouchida and Yoko Nakatani and Ritsuo Nishiuchi and Tadashi Yoshino and Kazuhiko Hayashi and Tadaatsu Akagi and Yoshiki Seino",
year = "2003",
month = "12",
doi = "10.1097/01.LAB.0000106503.65258.2B",
language = "English",
volume = "83",
pages = "1849--1858",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Activated Proliferation of B-Cell Lymphomas/Leukemias with the SHP1 Gene Silencing by Aberrant CpG Methylation

AU - Koyama, Maho

AU - Oka, Takashi

AU - Oouchida, Mamoru

AU - Nakatani, Yoko

AU - Nishiuchi, Ritsuo

AU - Yoshino, Tadashi

AU - Hayashi, Kazuhiko

AU - Akagi, Tadaatsu

AU - Seino, Yoshiki

PY - 2003/12

Y1 - 2003/12

N2 - Previously we showed reduced protein and mRNA expression of the SHP1 gene in lymphoma/leukemia cell lines and patient specimens by Northern blot, RT-PCR, Western blot, and immunohistochemical analyses. In this study, aberrant methylation in the SHP1 gene promoter was detected in many B-cell leukemia/lymphoma cell lines as well as in patient specimens, including diffuse large B-cell lymphoma (methylation frequency 93%), MALT lymphoma (82%), mantle cell lymphoma (75%), plasmacytoma (100%) and follicular lymphoma (96%) by methylation-specific PCR, bisulfite sequencing, and restriction enzyme-mediated PCR analyses. The methylation frequency was significantly higher in high-grade MALT lymphoma cases (100%) than in low-grade MALT lymphoma cases (70%), which correlated well with the frequency of no expression of SHP1 protein in high-grade (80%) and low-grade MALT lymphoma (54%). It suggests that the SHP1 gene silencing with aberrant CpG methylation relates to the lymphoma progression. SHP1 protein expression was recovered in B-cell lines after the treatment of the demethylating reagent: 5-aza-2′-deoxycytidine. Transfection of the intact SHP1 gene to the hematopoietic cultured cells, which show no expression of the SHP1 gene, induced growth inhibition, indicating that gene silencing of the SHP1 gene by aberrant methylation plays an important role to get the growth advantage of the malignant lymphoma/leukemia cells. The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. These data support the possibility that the SHP1 gene is one of the tumor suppressor genes.

AB - Previously we showed reduced protein and mRNA expression of the SHP1 gene in lymphoma/leukemia cell lines and patient specimens by Northern blot, RT-PCR, Western blot, and immunohistochemical analyses. In this study, aberrant methylation in the SHP1 gene promoter was detected in many B-cell leukemia/lymphoma cell lines as well as in patient specimens, including diffuse large B-cell lymphoma (methylation frequency 93%), MALT lymphoma (82%), mantle cell lymphoma (75%), plasmacytoma (100%) and follicular lymphoma (96%) by methylation-specific PCR, bisulfite sequencing, and restriction enzyme-mediated PCR analyses. The methylation frequency was significantly higher in high-grade MALT lymphoma cases (100%) than in low-grade MALT lymphoma cases (70%), which correlated well with the frequency of no expression of SHP1 protein in high-grade (80%) and low-grade MALT lymphoma (54%). It suggests that the SHP1 gene silencing with aberrant CpG methylation relates to the lymphoma progression. SHP1 protein expression was recovered in B-cell lines after the treatment of the demethylating reagent: 5-aza-2′-deoxycytidine. Transfection of the intact SHP1 gene to the hematopoietic cultured cells, which show no expression of the SHP1 gene, induced growth inhibition, indicating that gene silencing of the SHP1 gene by aberrant methylation plays an important role to get the growth advantage of the malignant lymphoma/leukemia cells. The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. These data support the possibility that the SHP1 gene is one of the tumor suppressor genes.

UR - http://www.scopus.com/inward/record.url?scp=0347995024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347995024&partnerID=8YFLogxK

U2 - 10.1097/01.LAB.0000106503.65258.2B

DO - 10.1097/01.LAB.0000106503.65258.2B

M3 - Article

C2 - 14691303

AN - SCOPUS:0347995024

VL - 83

SP - 1849

EP - 1858

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 12

ER -